Antimicrobial peptides and bacteriocins: alternatives to traditional antibiotics by Sang, Yongming & Blecha, Frank
Antimicrobial peptides and bacteriocins:
alternatives to traditional antibiotics
Yongming Sang and Frank Blecha*
Department of Anatomy and Physiology, Kansas State University, Manhattan, KS 66506, USA
Received 26 August 2008; Accepted 19 September 2008; First published online 5 November 2008
Abstract
Antimicrobial peptides (AMPs) are ubiquitous, gene-encoded natural antibiotics that have
gained recent attention in the search for new antimicrobials to combat infectious disease. In
multicellular organisms, AMPs, such as defensins and cathelicidins, provide a coordinated
protective response against infection and are a principal component of innate immunity in
vertebrates. In unicellular organisms, AMPs, such as bacteriocins, function to suppress
competitor species. Because many AMPs kill bacteria by disruption of membrane integrity and
are thus thought to be less likely to induce resistance, AMPs are being extensively evaluated as
novel antimicrobial drugs. This review summarizes and discusses the antibiotic properties of
AMPs highlighting their potential as alternatives to conventional antibiotics.
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Introduction
Antimicrobial peptides (AMPs): ubiquitous
natural antibiotics
Small biological molecules (<10 kDa) with direct anti-
microbial activity, including enzymatically synthesized
compounds and ribosomal-synthesized AMPs, provide
effective microbial defense for all organisms from bacteria
to mammals (Beutler, 2004; Hancock and Sahl, 2006). The
discovery and development of conventional antibiotics,
which are primarily based on bacteria- or fungi-generated
antimicrobial compounds, have led to dramatic improve-
ments in the ability to treat infectious diseases and
significant increases in food animal production. Unques-
tionably, antibiotics represent one of the major scientific
and medical advances of the 20th century (Gordon et al.,
2005; McPhee and Hancock, 2005). Although antibiotic
therapy is still the first choice to combat microbial
infections in humans and animals, the prevalence of
bacterial resistance to conventional antibiotics is a
growing public health concern. This has driven the search
for new antimicrobials that are broadly effective and less
likely to induce antimicrobial resistance.
Natural gene-encoded AMPs are a diverse group of
innate immune molecules present in all organisms.
Mature AMPs generally contain 12–100 amino acid
residues, possess a net positive charge and an amphi-
pathic structure that facilitates interaction with negatively
charged microbial membranes or other cellular targets
(Yeaman and Yount, 2007; Linde et al., 2008; Sang and
Blecha, 2008). A list of the general properties of AMPs,
including primary structural properties and antimicrobial
activities, is presented in Table 1. Compared with
conventional antibiotics, which are generally active
against bacteria or fungi, AMPs often exert activity against
a broad spectrum of micro-organisms including bacteria,
fungi, parasites, enveloped viruses and even some cancer
cells. In addition, unlike conventional antibiotics, which
generally target a metabolic enzyme and may selectively
induce resistance in micro-organisms, AMPs kill microbes
mainly by membrane-targeting pore-forming mechanisms
(Table 2), a mechanism that is inherently more difficult
for microbes to circumvent by developing resistance
(Boman, 2003; Hancock and Sahl, 2006). AMPs have been
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fungal peptide antibiotics, plant thionins and defensins,
insect defensins and cecropins, amphibian magainins and
temporins, as well as defensins and cathelicidins from
higher vertebrates (McPhee and Hancock, 2005; Yeaman
and Yount, 2007). This review will summarize and discuss
the antibiotic properties of AMPs with the aim of
highlighting their potential as alternatives to conventional
antibiotics.
Table 1. Examples and general properties of AMPs
Organism Class/subclass Examples Main structural properties Antimicrobial activity
LAB1 Class I and II
bacteriocins
Lantibiotics Class I: extensive
post-translational residue
modification. Either elongated
cationic or globular
conformation. Class II: very
diverse group. Pediocin-like
members conforming b-sheet
structures and a C-terminal
a-helix
Nanomolar range,
active against
closely related or
broad-spectrum
Gram-positive
bacteria
Class I: nisin, mersacidin;
non-lantibiotics.
Class II: pediocin, PA1,
enterocin AS48
Other
bacteria
(e.g. E. coli)2
Bacteriocins Colicins, microcins a-Helix-rich globular structure Nanomolar range,
active against
Enterobacteriaceae
Fungi3 Fungal defensins Plectasin Cysteine-rich, containing two
antiparallel b-sheets and an
a-helix
MIC: 1–35 mg/ml for
multiple antibiotic-
resistant Gram-
positive bacteria
Plants4 Plant defensins Ib-AMP1–4 and cyclotides Cysteine-rich, containing
antiparallel b-sheets, and
cyclotides with cyclic
backbone and cysteine knot
Micromolar range:
antifungal (Ib-
AMPs), anti-HIV,
anti-parasites
(cyclotides)
Insects/
amphibians5
Insect/
amphibian
cationic
peptides
Cecropin A, mellitin,
magainins, temporins
High basic residue content,
form a-helix containing
structures in membrane
Micromolar range
active against
multidrug-resistant
bacteria
Arachnida/
vertebrates6
Venom toxins/
b-defensins
Defensin-like toxins (DLTs)
in venom, and b-defensins
b-Sheets and disulfide bonds
form into b-hairpins,
and D-amino acid
post-translational
modification in DLTs
Micromolar range,
active against
multidrug-resistant
bacteria mostly in a
salt-dependent
manner
Mammals7 a-Defensins Human neutrophil defensins,
enteric and epithelial
defensins
b-Sheets and disulfide bonds
form into b-hairpins
Micromolar range
active against
multidrug-resistant
bacteria, and fungi
and viruses
q-Defensins
b-Defensins
Higher
vertebrates8
Cathelicidins Human LL-37, porcine
PR-39, bovine indolicidin
Contain a cathelin leader
sequence with an
amphipathic cationic
mature peptide
Micromolar range
active against
multidrug-resistant
bacteria, and fungi
and viruses
Humans9 Others Lactoferricin, and
antimicrobial domain of
lysozyme
Derived anionic/cationic
antimicrobial fragments
from lactoferrin, casein
and lysozyme
Micromolar range
active against
multidrug-resistant
bacteria
1Willey et al., 2007; Field et al., 2008.
2Duquesne et al., 2007; Nes et al., 2007.
3Mygind et al., 2005.
4Colgrave et al., 2008; Ireland et al., 2008; Marcos et al., 2008.
5Bechinger, 1997; Giacometti et al., 2003.
6Yeaman and Yount, 2007; Warren et al., 2008.
7Selsted and Ouellette, 2005; Lehrer, 2007.
8Zanetti, 2005.
9Brogden, 2005.
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Bacteriocins: bacterial AMPs
Bacteriocins are bacterially produced, small, heat-
stable peptides that bacteria use to compete against other
bacteria of the same species (narrow spectrum) or against
bacteria of other genera (broad spectrum) (Cotter et al.,
2005). One or several bacteriocins have been identified or
are believed to exist in every species of bacteria and
archaea (Cotter et al., 2005; Willey and van der Donk,
2007). A current bacteriocin database (Hammami et al.,
2007; http://www.cck.rnu.tn/pfba/bactibase/main.php)
lists 145 entries including 39 lanthionine-containing
bacteriocins (Class I), 40 non-lanthionine-containing
bacteriocins (Class II) and other unclassified entries,
likely bacteriolysins (Cotter et al., 2005; Willey and van
der Donk, 2007). Class I bacteriocins are small peptides
(18–39 residues) and are commonly called lantibiotics
because of the lanthionine or b-methyllanthionine resi-
dues that they contain. These unusual residues are formed
during post-translational modification and enzymatically
crosslink a dehydrated serine/threonine to a neighboring
cysteine, resulting in intramolecular covalent bridges
(Cotter et al., 2005; Willey and van der Donk, 2007). In
contrast, Class II bacteriocins constitute a very diverse
group and are not subject to this extensive post-
translational modification. Class III bacteriolysins are
large, heat-labile proteins that catalyze the hydrolysis of
bacterial cell walls resulting in autolysis of targeted
bacteria. The majority of Class I and Class II bacteriocins
are active in the nanomolar range against Gram-positive
bacteria in closely related species or in a broad-spectrum
manner for many species.
The most promising bacteriocins in development as
antibiotics are those produced by lactic acid bacteria
(LAB) with the core genera including Lactobacillus,
Lactococcus, Leuconostoc, Pediococcus and Streptococcus.
Because of the long history of using LAB in the processing
of fermented foods, the antimicrobial and safety informa-
tion for LAB in food preservation is widely accepted. In
addition, LAB are used extensively as probiotics in food
processing and preservation (De Vuyst and Leroy, 2007;
Sit and Vederas, 2008), and LAB-derived bacteriocins
will likely enter the working pharmacopeia as oral or
gastrointestinal antibiotics (Rossi et al., 2008). Examples
of LAB-derived bacteriocins include nisin, mersacidin,
lacticin 481 and lacticin 3147. Among these, nisin has
been approved for commercial use in some food
processing applications and as an anti-infective for bovine
mastitis (Cotter et al., 2005; Dufour et al., 2007), and
mersacidin has been evaluated in preclinical tests to treat
Gram-positive infections (Hancock and Sahl, 2006).
Lacticin 3147, a two-peptide lantibiotic, has shown
promise in preventing mastitis infections (Crispie et al.,
2005) and as a food preservative (Gardiner et al., 2007).
Importantly, several bacteriocins, including lacticin 3147,
mersacidin and leucocin A, display potent activity against
antibiotic-resistant bacterial strains such as vancomycin-
resistant enterococci (VRE) and methicillin-resistant
Staphylococcus aureus (MRSA) (Kruszewska et al., 2004;
Sit and Vederas, 2008). In addition to food-introduced
LAB, gastrointestinal commensal LAB (enterococci and
streptococci) and microflora of the family Enterobacter-
iaceae produce a large panel of bacteriocins, such as
enterocins, salivaricins, colicins and microcins. These
bacteriocins have significant potential for probiotic or
antibiotic use after suitable biotechnological modifica-
tions are developed (Duquesne et al., 2007; Nes et al.,
2007).
Table 2. Characteristics and applications of biological antimicrobials
Biological antimicrobials
Conventional antibiotics
Enzymatically synthesized compounds
Antimicrobial peptides
Ribosomal gene-encoded peptides
Examples1
Penicillin Canine cathelicidin Canine b-defensin-1
Molecular characteristics Small compounds <2000 Da, easy to
synthesize with lower production cost
Small amphipathic peptides <10 kDa,
feasible to synthesize with higher
production cost
Antimicrobial spectrum Most are active against a subclass of microbes
with low side effects
Most are broadly active and
multifunctional with potential side effects
Primary mechanism of action Metabolic inhibition, easy to develop bacterial
resistance
Plasma membrane disruption, hard to
develop bacterial resistance
Application Conventional antibiotic therapies Prebiotics, probiotics; transgenic animals;
new generation of antibiotics
1Structure information for penicillin is from the public domain (http://www.hopkins-abxguide.org/). Structures of canine
b-defensin-1 and cathelicidin were adapted from our previous work (Sang et al., 2005; Sang et al., 2007).
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Fungal AMPs
The most widely used and historic antibiotic to date,
penicillin, is from the fungus Penicillium chrysogenum,
previously named Penicillium notatum. In addition,
many peptide antimicrobials are produced by fungi. For
example, soil-fungi peptide antibiotics named peptaibols
(small peptides usually containing a-aminoisobutyric acid
and a C-terminal alcohol) have potent antibacterial and
antifungal properties (Duclohier, 2007). The antimicrobial
properties of peptaibols derive from their amphipathic,
helical structure that facilitates lytic pore formation in
membranes. Although peptaibols are peptide antibiotics
they are not gene-encoded, ribosomal-produced AMPs;
instead they use a multi-enzyme, non-ribosomal peptide
sythetase complex (peptaibol synthetase) for their
biosynthesis (Leitgeb et al., 2007). Hundreds of peptaibol
sequences are compiled in the Peptaibol Database
(http://www.cryst.bbk.ac.uk/peptaibol/home.shtml).
Fungal genomes also encode abundant cysteine-rich
AMPs consisting of a-helix and b-sheet structures,
collectively called defensin-like peptides (Zhu, 2008).
Plectasin is the first identified fungal defensin and is
active against antibiotic-resistant strains of Streptococcus
pneumoniae with efficacy in treating peritonitis and
pneumonia in mice (Mygind et al., 2005) (Table 1).
Bioinformatics analysis of fungal genomes reveals six
families of fungal defensin-like peptides, among which
three families are ancestral to defensin molecules from
plants, insects and invertebrates (Zhu, 2008). Indeed,
evolutionarily, cysteine-rich defensin-like peptides have
been suggested to be the most diverse group of AMPs
existing in all cellular organisms (Yeaman and Yount,
2007; Zhu, 2008).
Plant AMPs
It has been estimated that there are about 300 genes
encoding defensins in plants (Silverstein et al., 2005;
Thevissen et al., 2007). Although direct antimicrobial
activity of most plant defensins against animal pathogens
has not been reported, four cysteine-rich plant AMPs and
their synthetic analogues are potent against bacterial and
fungal infections. These AMPs were isolated from seeds
of Impatiens balsamina, an herb with a long history
of use among Asian people to treat infectious diseases
(Thevissen et al., 2007; Marcos et al., 2008). Another
fascinating subgroup of plant AMPs are cyclotides
characterized by a cyclic backbone and knotted disulfide
bonds resulting from cyclization. Plant cyclotides were
recently shown to be highly active against HIV-
infected cells (Ireland et al., 2008) and to significantly
suppress the development of gastrointestinal nematode
parasites in livestock (Barbeta et al., 2008; Colgrave et al.,
2008).
Animal AMPs
Most animals possess defensins or defensin-like peptides.
Indeed defensin-like peptides are present in venom
toxins from arthropod and reptile species such as
scorpions and snakes (Whittington et al., 2008), and
genome analysis of the platypus suggests that defensin-
like peptides are an evolutionary signature (Warren et al.,
2008; Whittington et al., 2008). Mammals possess the most
diverse groups of defensins. Three subgroups of mamma-
lian defensins, a-, b- and q-defensins, have been classified
based on the differential connections of their three
disulfide bridges (Ganz, 2003; Selsted and Ouellette,
2005). Defensins have evolved in mammals with a- and q-
defensins only appearing in species later than glires and
some primate clades (Selsted and Ouellette, 2005; Lehrer,
2007; Lynn and Bradley, 2007; Sang and Blecha, 2008).
In addition to cysteine-rich AMPs, there are other
prominent subgroups of AMPs in animals characterized
on the basis of primary or secondary peptide structure
(Brogden, 2005). One subgroup is characterized by an
abundant number of cationic peptides containing basic
and/or hydrophobic residues at a high ratio and many of
them conform into a-helical structures in membrane-
mimetic environments. Examples of these subgroups
include mammalian cathelicidins, amphibian magainins
and maximins, and insect cecropins. Some members of
this subgroup, such as cathelicidins, are rich in certain
residues such as proline (e.g. porcine PR-39), phenylala-
nine (e.g. porcine prophenins) and tryptophan (e.g.
bovine indolicidin), which may contribute to their
‘multi-hitting’ model of antimicrobial responses (McPhee
and Hancock, 2005; Hancock and Sahl, 2006; Hale and
Hancock, 2007) (Fig. 1). The second subgroup of AMPs
includes antimicrobial fragments derived from large
proteins such as lactoferricin from lactoferrin and the
antimicrobial domain of lysozyme (Brogden, 2005)
(Table 1). Potent activity against a broad spectrum of
micro-organisms including bacteria, fungi, enveloped
viruses and tumor cells has been observed in members
of these animal AMPs (Brogden, 2005) plus multiple roles
with respect to immunoregulation and cell signaling
(Hancock and Sahl, 2006; Zaiou, 2007). These examples
illustrate the diversity of AMPs and suggest that they may
be a rich source for future antibiotic design and drug
development. Indeed, multiple AMPs or analogues are in
development for antimicrobial and immunoregulatory
therapies (Gordon et al., 2005; McPhee and Hancock,
2005; Hancock and Sahl, 2006).
AMPs as natural antibiotics: antimicrobial activity,
mechanism of action and current status in
development
Similar to traditional antibiotics, most AMPs are highly
active against bacteria and fungi. However, many AMPs,
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including plant cyclotides, and animal defensins and
cathelicidins, also possess antiviral or anti-parasite activity
(Table 1). Generally, bacteriocins are extremely active
against related Gram-positive bacteria or Enterobacter-
iaceae with minimal inhibitory concentration (MIC) in
the nanomolar range. Several bacteria that produce
bacteriocins are food-borne pathogens, such as Listeria
monocytogenesis and antibiotic-resistant strains of
Salmonella spp., Campylobacter spp., Escherichia coli
and Enterococcus spp. (Kang and Lee, 2005; Nes et al.,
2007; Sit and Vederas, 2008; Svetoch et al., 2008).
Therefore, bacteriocins, especially lantibiotics, have
promise as antibiotics to meet the requirements of food
preservation and in preventing infections from food-
borne pathogens (Nes et al., 2007; Sit and Vederas, 2008).
The primary bactericidal mechanism of bacteriocins is
through membrane pore formation as shown for most
lantibiotics. However, some bacteriocins also attack other
cellular targets such as mersacidin interaction with lipid II
to prevent cell-wall synthesis, microcin J25 inhibition of
bacterial RNA synthesis and duramycin-C inhibition of
bacterial phospholipase A2. Other bacteriocins like nisin
use more than one mechanism (membrane pore forma-
tion and disruption of cell-wall synthesis) to kill targeted
bacteria. The antimicrobial capacity of two-peptide
bacteriocins such as Class I lacticin 3147 and Class II
lactacin-F requires the combined activity of both partners
to dissipate membrane potential, to induce ion leakage
and/or to interfere with cellular ATP production (Fig. 1)
(Cotter et al., 2005; Willey et al., 2007).
Membrane-targeting mechanisms are the most
conserved killing mechanisms of AMPs identified from
plants, insects and vertebrate animals (Table 1 and Fig. 1).
Through their net-positive surface charge and/or amphi-
pathic structure, AMPs undergo a pore-formation process
of membrane attachment, insertion and permeabilization
(Brogden, 2005). In a recently proposed two-state model
based on studies of representative cysteine-rich AMPs, it is
posited that AMPs initially assemble parallel to the plane
of the membrane and cause membrane thinning in
proportion to the peptide/lipid ratio of the membrane.
As the peptides continue assembling on the membrane
surface and exceed the peptide/lipid ratio threshold, the
interaction enters a second state, where alignment of the
peptide assemblages becomes perpendicular to the plane
of the membrane and form transmembrane pores (Huang,
2006; Jang et al., 2006). Using solid-state NMR techniques,
Mani et al. (2006) accurately measured the properties of
Conventional antibiotics
Bacterial cell
Antimicrobial peptides
Fig. 1. Mechanisms of action of conventional antibiotics and AMPs. Bactericidal mechanisms of AMPs are illustrated with an
emphasis on the propensity to membrane disruption. AMP-related aspects were adapted with permission from Macmillan
Publishers: Nature Reviews: Microbiology (Brogden, 2005) and Nature Biotechnology (Hancock and Sahl, 2006).
Conventional antibiotic information was adapted from a public domain (http://www.hopkins-abxguide.org/).
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the lytic pores induced by porcine protegrin (a cysteine-
rich cathelicidin) on a lipid bilayer that mimics the
bacterial membrane. Although AMPs with diverse struc-
tural properties may undergo different kinetic processes,
this model shows that cysteine-rich AMPs like defensins
and protegrins insert a pore in the lipid bilayer through a
b-barrel mechanism. In addition, due to the distinct lipid
composition (mainly cholesterol content) and relative
neutral charge of eukaryotic membranes compared with
bacterial membranes, the effective concentration of AMPs
to induce changes in eukaryotic membranes is higher
than the lytic dose on bacteria (Huang, 2006; Jang et al.,
2006; Mani et al., 2006). The different kinetics of AMP
interaction with eukaryotic and bacterial membranes
partially explain why host AMPs discriminate between
host cells and bacteria. In addition, many higher
vertebrates have evolved other mechanisms to target
their AMPs to pathogens while limiting damage to
themselves, including (i) storage of potent AMPs in
special cells or cell compartments such as neutrophils
and neutrophil granules (Selsted and Ouellette, 2005;
Lehrer, 2007), (ii) controlled synthesis of mature AMPs
only in functional organs such as synthesis of killing
toxins in venom glands of arthropods, reptiles and the
platypus (Warren et al., 2008), (iii) differential processing
of AMP’s mature peptides to balance antimicrobial activity
such as multiple mature forms of human LL-37 in sweat
on the skin surface (Murakami et al., 2004), and (iv)
interference with AMP activity by other coexisting
molecules such as serum proteins and mucins (Brogden,
2005). Similarly, bacteria also have protective mechanisms
to limit harm from self-produced bacteriocins. For
example, the genes for lantibiotic biosynthesis, regulation
and self-immunity are found in clusters allowing for
coordinated expression (Rossi et al., 2008). Furthermore,
in the case of lantibiotics, immunity is provided by
specific immune proteins and/or by sensing proteins to
regulate bacteriocin synthesis or transport. For example, a
single immune protein PepI protects Staphylococcus
epidermidis from its bacteriocin Pep5 by masking the
target molecule of Pep5 on the membrane. NisI, which is
an outer membrane lipoprotein of Lactococcus lactis,
arrests nisins to limit local concentrations from reaching
the membrane of nisin-producers; however, NisI cannot
protect L. lactis from closely related lantibiotics produced
by Bacillus subtilis, indicating that self-immunity to a
bacteriocin is very specific (Willey et al., 2007; Draper
et al., 2008).
The overall antimicrobial effect of an AMP in vivo,
which is manifested by suppression/elimination of infec-
tion by a pathogen, can result from both its direct
antimicrobial activity and indirect immune regulatory
functions. In this context, most AMPs in higher verte-
brates, such as mammalian defensins and cathelicidins,
have been shown to be multifunctional and because of
this property are often referred to as host defense
peptides (Hancock and Sahl, 2006; Zaiou, 2007). A partial
list of these immunoregulatory functions exerted by
mammalian antimicrobial host defense peptides includes
chemoattractant activity for immune cells, inhibition of
oxidative burst of phagocytes, promotion of angiogenesis
and wound healing, regulation of development and
function of male reproductive cells, and induction of
autoimmunity (Hancock and Sahl, 2006; Zaiou, 2007).
Although these multifunctional properties may increase
the drug development potential of AMPs, some may also
cause limitations in the development of antibiotics. Other
challenges to AMP-based drug development include
cytotoxicity and the higher cost of peptide synthesis
(Hancock and Sahl, 2006; Scott et al., 2007). Finally,
although microbial resistance is usually considered less
likely for AMPs than conventional antibiotics, some
mechanisms of resistance to AMPs have been identified
(Gunn, 2008; Kraus and Peschel, 2008); this should be
considered in developing and using AMP-based drugs.
Several recent publications have discussed and
reviewed AMP-based drug development (Andre`s and
Dimarcq, 2005; Gordon et al., 2005; McPhee and
Hancock, 2005; Hancock and Sahl, 2006). Most AMP-
based antibiotic studies are in the discovery or preclinical
stages with some proceeding to clinical trials. Nisin, a LAB
lantibiotic, is one of few examples of AMP-based
antibiotic therapies that have been commercialized. Other
AMP-based drugs that have progressed to clinical trials,
such as those derived from insect cecropin B and bovine
indolicidin (Hancock and Sahl, 2006; Scott et al., 2007),
have been developed to treat wounds or skin-related
infections in humans, applications that may also be used
in veterinary medicine. Some drugs in testing are
derivatives of AMPs that have been modified to improve
their antimicrobial activity. These modifications include
introducing non-natural residues like D-amino acids,
addition of C-terminal amidation and catalysis of cyclic
formation, which are believed to improve stability and
activity against targeted micro-organisms as shown in
natural bacteriocins, plant cyclotides and primate
q-defensins (Lehrer, 2007; Bansal et al., 2008; Ireland
et al., 2008). Therefore, optimized design of synthetic
peptides based on knowledge from natural AMP studies
(the concept of ‘designer AMPs’) may provide a feasible
way to increase novel drug development (Scott et al.,
2007; Jenssen et al., 2008).
Generation of transgenic animals and plants by
xenobiotic expression of an AMP from other species is
another approach to improve disease resistance and
growth performance in food animals. Transgenic animals
are also potent bioreactors to produce AMP-containing
prebiotics or to purify natural AMPs. For example,
transgenic cows (Hyvo¨nen et al., 2006), rabbits (Han
et al., 2008) and goats (Zhang et al., 2008) expressing
human lactoferrin in milk were produced to enhance
health effects for dairy consumers and to provide large-
scale production of human lactoferrin. Although trans-
genic cows with xenobiotic expression of human
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lactoferrin did not exhibit enhanced protection against an
E. coli intramammary infection (Hyvo¨nen et al., 2006),
transgenic mice expressing porcine lactoferrin in milk
promoted offspring growth (Wu et al., 2007) and
resistance to foot-and-mouth disease (Chen et al., 2008).
Broiler diets containing rice that was genetically altered to
express human lactoferrin or lysozyme protected chick
intestinal tracts similar to subtherapeutic antibiotics and
improved small intestinal architecture (Humphrey et al.,
2002). Moreover, transgenic mice with ectopic expression
of human intestinal defensin-5 (HD-5) (Salzman et al.,
2003), porcine cathelicidin PR-39 (Lee et al., 2005) and
protegrin-1 (Cheung et al., 2008) had significantly
enhanced protection against enteric salmonellosis, bacter-
ial skin infection and Actinobacillus suis infection,
respectively. In contrast, transgenic mice overexpressing
mouse AMPs, such as b-defensin-6 (Yamaguchi et al.,
2007) or mouse cathelicidin (Lee et al., 2005), exhibited
no increased resistance.
Concluding remarks
AMPs, a group of innate immune effectors with special
antimicrobial mechanisms that have endured the selective
pressure of years of evolution, provide an attractive
platform from which to develop novel antibiotics
(Beutler, 2004). The recent realization that AMPs are an
essential component of microbe–host mutualism under-
scores the important immunoregulatory role of AMPs in
addition to their well-known direct antimicrobial activity.
Thus, these peptides will continue to be investigated for
novel therapeutic strategies based on their multifunctional
properties as antimicrobials and host defense peptides
(Hancock and Sahl, 2006; Hoskin and Ramamoorthy,
2008; Steinstraesser et al., 2008).
Acknowledgments
We thank former graduate and postdoctoral students,
technicians and collaborators who made this work
possible and Danielle Goodband for her excellent
technical support. This work was supported in part by
USDA NRI Competitive Grant 2006-35204-17337.
References
Andre`s E and Dimarcq JL (2005). Clinical development of
antimicrobial peptides. International Journal of Antimicro-
bial Agents 25: 448–449.
Bansal PS, Torres AM, Crossett B, Wong KK, Koh JM, Geraghty
DP, Vandenberg JI and Kuchel PW (2008). Substrate
specificity of platypus venom L-to-D-peptide isomerase.
Journal of Biological Chemistry 283: 8969–8975.
Barbeta BL, Marshall AT, Gillon AD, Craik DJ and Anderson MA
(2008). Plant cyclotides disrupt epithelial cells in the midgut
of lepidopteran larvae. Proceedings of the National
Academy of Science, USA 105: 1221–1225.
Bechinger B (1997). Structure and functions of channel-forming
peptides: magainins, cecropins, melittin and alamethicin.
Journal of Membrane Biology 156: 197–211.
Beutler B (2004). Innate immunity: an overview. Molecular
Immunology 40: 845–859.
Boman HG (2003). Antibacterial peptides: basic facts and
emerging concepts. Journal of Internal Medicine 254:
197–215.
Brogden KA (2005). Antimicrobial peptides: pore formers or
metabolic inhibitors in bacteria? Nature Reviews Micro-
biology 3: 238–250.
Chen HL, Wang LC, Chang CH, Yen CC, Cheng WT, Wu SC,
Hung CM, Kuo MF and Chen CM (2008). Recombinant
porcine lactoferrin expressed in the milk of transgenic mice
protects neonatal mice from a lethal challenge with
enterovirus type 71. Vaccine 26: 891–898.
Cheung QC, Turner PV, Song C, Wu D, Cai HY, MacInnes JI and
Li J (2008). Enhanced resistance to bacterial infection in
protegrin-1 transgenic mice. Antimicrobial Agents and
Chemotherapy 52: 1812–1819.
Colgrave ML, Kotze AC, Huang YH, O’Grady J, Simonsen SM
and Craik DJ (2008). Cyclotides: natural, circular plant
peptides that possess significant activity against gastro-
intestinal nematode parasites of sheep. Biochemistry 47:
5581–5589.
Cotter PD, Hill C and Ross RP (2005). Bacteriocins: developing
innate immunity for food. Nature Reviews Microbiology 3:
777–788.
Crispie F, Twomey D, Flynn J, Hill C, Ross P and Meaney W
(2005). The lantibiotic lacticin 3147 produced in a milk-
based medium improves the efficacy of a bismuth-based
teat seal in cattle deliberately infected with Staphylococcus
aureus. Journal of Dairy Research 72: 159–167.
Draper LA, Ross RP, Hill C and Cotter PD (2008). Lantibiotic
immunity. Current Protein and Peptide Science 9: 39–49.
Duclohier H (2007). Peptaibiotics and peptaibols: an alternative
to classical antibiotics? Chemistry and Biodiversity 4: 1023–
1026.
Dufour A, Hindre´ T, Haras D and Le Pennec JP (2007). The
biology of lantibiotics from the lacticin 481 group is coming
of age. FEMS Microbiology Reviews 31: 134–167.
De Vuyst L and Leroy F (2007). Bacteriocins from lactic acid
bacteria: production, purification, and food applications.
Journal of Molecular Microbiology and Biotechnology 13:
194–199.
Duquesne S, Destoumieux-Garzo´n D, Peduzzi J and Rebuffat S
(2007). Microcins, gene-encoded antibacterial peptides
from enterobacteria. Natural Product Reports 24: 708–
734.
Field D, Connor PM, Cotter PD, Hill C and Ross RP (2008). The
generation of Nisin variants with enhanced activity against
specific Gram positive pathogens. Molecular Microbiology
69: 218–230.
Ganz T (2003). Defensins: antimicrobial peptides of innate
immunity. Nature Reviews Immunology 3: 710–720.
Gardiner GE, Rea MC, O’Riordan B, O’Connor P, Morgan SM,
Lawlor PG, Lynch PB, Cronin M, Ross RP and Hill C (2007).
Fate of the two-component lantibiotic lacticin 3147 in the
gastrointestinal tract. Applied and Environmental Micro-
biology 73: 7103–7109.
Giacometti A, Cirioni O, Kamysz W, D’Amato G, Silvestri C, Del
Prete MS, Łukasiak J and Scalise G (2003). Comparative
activities of cecropin A, melittin, and cecropin A–melittin
peptide CA(1–7)M(2–9) NH2 against multidrug-resistant
nosocomial isolates of Acinetobacter baumannii. Peptides
24: 1315–1318.
Antimicrobial peptides and bacteriocins 233
Gordon YJ, Romanowski EG and McDermott AM (2005). A review
of antimicrobial peptides and their therapeutic potential as
anti-infective drugs. Current Eye Research 30: 505–515.
Gunn JS (2008). The Salmonella PmrAB regulon: lipopolysac-
charide modifications, antimicrobial peptide resistance and
more. Trends in Microbiology 16: 284–290.
Hale JD and Hancock RE (2007). Alternative mechanisms of
action of cationic antimicrobial peptides on bacteria. Expert
Review of Anti-infective Therapy 5: 951–959.
Hammami R, Zouhir A, Ben Hamida J and Fliss I (2007).
BACTIBASE: a web-accessible database for bacteriocin
characterization. BMC Microbiology 7: 89.
Han ZS, Li QW, Zhang ZY, Yu YS, Xiao B, Wu SY, Jiang ZL, Zhao
HW, Zhao R and Li J (2008). Adenoviral vector mediates
high expression levels of human lactoferrin in the milk of
rabbits. Journal of Microbiology and Biotechnology 18: 153–
159.
Hancock RE and Sahl HG (2006). Antimicrobial and host-defense
peptides as new anti-infective therapeutic strategies. Nature
Biotechnology 24: 1551–1557.
Hoskin DW and Ramamoorthy A (2008). Studies on anticancer
activities of antimicrobial peptides. Biochimica et Biophy-
sica Acta 1778: 357–375.
Huang HW (2006). Molecular mechanism of antimicrobial
peptides: the origin of cooperativity. Biochimica et
Biophysica Acta 1758: 1292–1302.
Humphrey BD, Huang N and Klasing KC (2002). Rice expressing
lactoferrin and lysozyme has antibiotic-like properties when
fed to chicks. Journal of Nutrition 132: 1214–1218.
Hyvo¨nen P, Suojala L, Orro T, Haaranen J, Simola O, Røntved C
and Pyo¨ra¨la¨ S (2006). Transgenic cows that produce
recombinant human lactoferrin in milk are not protected
from experimental Escherichia coli intramammary infec-
tion. Infection and Immunity 74: 6206–6212.
Ireland DC, Wang CK, Wilson JA, Gustafson KR and Craik DJ
(2008). Cyclotides as natural anti-HIV agents. Biopolymers
90: 51–60.
Jang H, Ma B, Woolf TB and Nussinov R (2006). Interaction of
protegrin-1 with lipid bilayers: membrane thinning effect.
Biophysical Journal 91: 2848–2859.
Jenssen H, Fjell CD, Cherkasov A and Hancock RE (2008). QSAR
modeling and computer-aided design of antimicrobial
peptides. Journal of Peptide Science 14: 110–114.
Kang JH and Lee MS (2005). Characterization of a bacteriocin
produced by Enterococcus faecium GM-1 isolated from an
infant. Journal of Applied Microbiology 98: 1169–1176.
Kraus D and Peschel A (2008). Staphylococcus aureus evasion of
innate antimicrobial defense. Future Microbiology 3: 437–
451.
Kruszewska D, Sahl HG, Bierbaum G, Pag U, Hynes SO and
Ljungh A (2004). Mersacidin eradicates methicillin-resistant
Staphylococcus aureus (MRSA) in a mouse rhinitis model.
Journal of Antimicrobial Chemotherapy 54: 648–653.
Lee PH, Ohtake T, Zaiou M, Murakami M, Rudisill JA, Lin KH and
Gallo RL (2005). Expression of an additional cathelicidin
antimicrobial peptide protects against bacterial skin infec-
tion. Proceedings of the National Academy of Sciences, USA
102: 3750–3755.
Lehrer RI (2007). Multispecific myeloid defensins. Current
Opinion in Hematology 14: 16–21.
Leitgeb B, Szekeres A, Manczinger L, Va´gvo¨lgyi C and Kredics L
(2007). The history of alamethicin: a review of the most
extensively studied peptaibol. Chemistry and Biodiversity
4: 1027–1051.
Linde A, Ross CR, Davis EG, Dib L, Blecha F and Melgarejo T
(2008). Innate immunity and host defense peptides in
veterinary medicine. Journal of Veterinary Internal Medi-
cine 22: 247–265.
Lynn DJ and Bradley DG (2007). Discovery of alpha-defensins in
basal mammals. Developmental and Comparative Immu-
nology 31: 963–967.
Mani R, Cady SD, Tang M, Waring AJ, Lehrer RI and Hong M
(2006). Membrane-dependent oligomeric structure and
pore formation of a beta-hairpin antimicrobial peptide in
lipid bilayers from solid-state NMR. Proceedings of the
National Academy of Sciences, USA 103: 16242–16247.
Marcos JF, Mun˜oz A, Pe´rez-Paya´ E, Misra S and Lo´pez-Garci´a B
(2008). Identification and rational design of novel anti-
microbial peptides for plant protection. Annual Review of
Phytopathology 46: 273–301.
McPhee JB and Hancock RE (2005). Function and therapeutic
potential of host defence peptides. Journal of Peptide
Science 11: 677–687.
Murakami M, Lopez-Garcia B, Braff M, Dorschner RA and Gallo
RL (2004). Postsecretory processing generates multiple
cathelicidins for enhanced topical antimicrobial defense.
Journal of Immunology 172: 3070–3077.
Mygind PH, Fischer RL, Schnorr KM, Hansen MT, So¨nksen CP,
Ludvigsen S, Ravento´s D, Buskov S, Christensen B, De
Maria L, Taboureau O, Yaver D, Elvig-Jørgensen SG,
Sørensen MV, Christensen BE, Kjaerulff S, Frimodt-Moller
N, Lehrer RI, Zasloff M and Kristensen HH (2005). Plectasin
is a peptide antibiotic with therapeutic potential from a
saprophytic fungus. Nature 437: 975–980.
Nes IF, Diep DB and Holo H (2007). Bacteriocin diversity in
Streptococcus and Enterococcus. Journal of Bacteriology
189: 1189–1198.
Rossi LM, Rangasamy P, Zhang J, Qiu XQ and Wu GY (2008).
Research advances in the development of peptide anti-
biotics. Journal of Pharmaceutical Sciences 97: 1060–1070.
Salzman NH, Ghosh D, Huttner KM, Paterson Y and Bevins CL
(2003). Protection against enteric salmonellosis in trans-
genic mice expressing a human intestinal defensin. Nature
422: 522–526.
Sang Y and Blecha F (2008). Porcine host defense peptides:
expanding repertoire and functions. Developmental and
Comparative Immunology, 2008 June 9 [Epub ahead of
print] doi:10.1016/j.dci.2008.05.006.
Sang Y, Ortega MT, Blecha F, Prakash O and Melgarejo T (2005).
Molecular cloning and characterization of three b-defensins
from canine testis. Infection and Immunity 73: 2611–2620.
Sang Y, Ortega MT, Rune K, Xiau W, Zhang G, Soulages JL,
Lushington GH, Fang K, Williams TD, Blecha F and
Melgarejo T (2007). Canine cathelicidin (K9CATH): gene
cloning, expression, and biochemical activity of a novel
pro-myeloid antimicrobial peptide. Developmental and
Comparative Immunology 31: 1278–1296.
Scott MG, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M,
Thompson A, Wang A, Lee K, Doria S, Hamill P, Yu JJ, Li Y,
Donini O, Guarna MM, Finlay BB, North JR and Hancock RE
(2007). An anti-infective peptide that selectively modulates
the innate immune response. Nature Biotechnology 25:
465–472.
Selsted ME and Ouellette AJ (2005). Mammalian defensins in the
antimicrobial immune response. Nature Immunology 6:
551–557.
Sit CS and Vederas JC (2008). Approaches to the discovery of
new antibacterial agents based on bacteriocins. Biochem-
istry and Cell Biology 86: 116–123.
Silverstein KA, Graham MA, Paape TD and VandenBosch KA
(2005). Genome organization of more than 300 defensin-
like genes in Arabidopsis. Plant Physiology 138: 600–610.
Steinstraesser L, Koehler T, Jacobsen F, Daigeler A, Goertz O,
Langer S, Kesting M, Steinau H, Eriksson E and Hirsch T
(2008). Host defense peptides in wound healing. Molecular
Medicine 14: 528–537.
234 Y. Sang and F. Blecha
Svetoch EA, Eruslanov BV, Perelygin VV, Mitsevich EV, Mitsevich
IP, Borzenkov VN, Levchuk VP, Svetoch OE, Kovalev YN,
Stepanshin YG, Siragusa GR, Seal BS and Stern NJ (2008).
Diverse antimicrobial killing by Enterococcus faecium E 50-
52 bacteriocin. Journal of Agricultural and Food Chemistry
56: 1942–1948.
Thevissen K, Kristensen HH, Thomma BP, Cammue BP
and Franc¸ois IE (2007). Therapeutic potential of antifungal
plant and insect defensins. Drug Discovery Today 12: 966–
971.
Warren WC, Hillier LW, Marshall Graves JA, Birney E, Ponting
CP, Gru¨tzner F, Belov K, Miller W, Clarke L, Chinwalla AT,
Yang S-P, Heger A, Locke DP, Miethke P, Waters PD,
Veyrunes F, Fulton L, Fulton B, Graves T, Wallis J, Puente X,
Lopez-Otin C, Ordonez GR, Eichler EE, Cheng LIN, Cheng
ZE, Deakin JE, Alsop A, Thompson K, Kirby P, Papenfuss
AT, Wakefield MJ, Olender T, Lancet D, Huttley GA, Smit
Arian FA, Pask A, Temple-Smith P, Batzer MA, Walker JA,
Konkel MK, Harris RS, Whittington CM, Wong ESW,
Gemmell NJ, Buschiazzo E, Vargas Jentzsch IM, Merkel A,
Schmitz J, Zemann A, Churakov G, Kriess JO, Brosius J,
Murchison EP, Sachidanandam SC, Hannon GJ, Tsend-
Ayush E, Mcmillan D and Attenborough R (2008). Genome
analysis of the platypus reveals unique signatures of
evolution. Nature 453: 175–183.
Whittington CM, Papenfuss AT, Bansal P, Torres AM, Wong ES,
Deakin JE, Graves T, Alsop A, Schatzkamer K, Kremitzki C,
Ponting CP, Temple-Smith P, Warren WC, Kuchel PW and
Belov K (2008). Defensins and the convergent evolution of
platypus and reptile venom genes. Genome Research 18:
986–994.
Willey JM and van der Donk WA (2007). Lantibiotics: peptides of
diverse structure and function. Annual Review of Micro-
biology 61: 477–501.
Wu SC, Chen HL, Yen CC, Kuo MF, Yang TS, Wang SR, Weng
CN, Chen CM and Cheng WT (2007). Recombinant porcine
lactoferrin expressed in the milk of transgenic mice
enhances offspring growth performance. Journal of Agri-
cultural and Food Chemistry 55: 4670–4677.
Yamaguchi Y, Nagase T, Tomita T, Nakamura K, Fukuhara S,
Amano T, Yamamoto H, Ide Y, Suzuki M, Teramoto S,
Asano T, Kangawa K, Nakagata N, Ouchi Y and Kurihara H
(2007). Beta-defensin overexpression induces progressive
muscle degeneration in mice. American Journal of Physiol-
ogy – Cell Physiology 292: C2141–C2149.
Yeaman MR and Yount NY (2007). Unifying themes in host
defence effector polypeptides. Nature Reviews Microbiology
5: 727–740.
Zaiou M (2007). Multifunctional antimicrobial peptides: ther-
apeutic targets in several human diseases. Journal of
Molecular Medicine 85: 317–329.
Zanetti M (2005). The role of cathelicidins in the innate host
defenses of mammals. Current Issues in Molecular Biology
7: 179–196.
Zhang J, Li L, Cai Y, Xu X, Chen J, Wu Y, Yu H, Yu G, Liu S,
Zhang A, Chen J and Cheng G (2008). Expression of active
recombinant human lactoferrin in the milk of transgenic
goats. Protein Expression and Purification 57: 127–135.
Zhu S (2008). Discovery of six families of fungal defensin-like
peptides provides insights into origin and evolution of the
CSalphabeta defensins. Molecular Immunology 45: 828–
838.
Antimicrobial peptides and bacteriocins 235
